QUOIN PHARMACEUTICALS LT-ADR (QNRX) Fundamental Analysis & Valuation

NASDAQ:QNRX • US74907L4095

Current stock price

5.9 USD
+0.16 (+2.79%)
Last:

This QNRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. QNRX Profitability Analysis

1.1 Basic Checks

  • In the past year QNRX has reported negative net income.
  • In the past year QNRX has reported a negative cash flow from operations.
  • In the past 5 years QNRX always reported negative net income.
  • QNRX had a negative operating cash flow in each of the past 5 years.
QNRX Yearly Net Income VS EBIT VS OCF VS FCFQNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • QNRX's Return On Assets of -214.33% is on the low side compared to the rest of the industry. QNRX is outperformed by 89.36% of its industry peers.
Industry RankSector Rank
ROA -214.33%
ROE N/A
ROIC N/A
ROA(3y)-64.59%
ROA(5y)-101.87%
ROE(3y)-126.09%
ROE(5y)-751.54%
ROIC(3y)N/A
ROIC(5y)N/A
QNRX Yearly ROA, ROE, ROICQNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for QNRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNRX Yearly Profit, Operating, Gross MarginsQNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. QNRX Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for QNRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QNRX Yearly Shares OutstandingQNRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
QNRX Yearly Total Debt VS Total AssetsQNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -21.03, we must say that QNRX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of QNRX (-21.03) is worse than 84.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.03
ROIC/WACCN/A
WACCN/A
QNRX Yearly LT Debt VS Equity VS FCFQNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • QNRX has a Current Ratio of 1.04. This is a normal value and indicates that QNRX is financially healthy and should not expect problems in meeting its short term obligations.
  • QNRX has a Current ratio of 1.04. This is amonst the worse of the industry: QNRX underperforms 85.88% of its industry peers.
  • QNRX has a Quick Ratio of 1.04. This is a normal value and indicates that QNRX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.04, QNRX is not doing good in the industry: 85.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 1.04
QNRX Yearly Current Assets VS Current LiabilitesQNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. QNRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 74.15% over the past year.
EPS 1Y (TTM)74.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 43.14% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.73%
EPS Next 2Y40.53%
EPS Next 3Y51.95%
EPS Next 5Y43.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNRX Yearly Revenue VS EstimatesQNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 50M 100M 150M
QNRX Yearly EPS VS EstimatesQNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -50K -100K -150K

More info and screens

Find the best growth stocksShow best growing peers

1

4. QNRX Valuation Analysis

4.1 Price/Earnings Ratio

  • QNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNRX Price Earnings VS Forward Price EarningsQNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNRX Per share dataQNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as QNRX's earnings are expected to grow with 51.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.53%
EPS Next 3Y51.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. QNRX Dividend Analysis

5.1 Amount

  • No dividends for QNRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

QNRX Fundamentals: All Metrics, Ratios and Statistics

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (4/10/2026, 8:00:01 PM)

5.9

+0.16 (+2.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)05-11
Inst Owners51.72%
Inst Owner Change0%
Ins Owners3.54%
Ins Owner Change1.03%
Market Cap9.54M
Revenue(TTM)N/A
Net Income(TTM)-13.77M
Analysts82.5
Price Target26.86 (355.25%)
Short Float %17.58%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.64%
Min EPS beat(2)-32.19%
Max EPS beat(2)16.91%
EPS beat(4)2
Avg EPS beat(4)1.27%
Min EPS beat(4)-32.19%
Max EPS beat(4)25.4%
EPS beat(8)5
Avg EPS beat(8)2.22%
EPS beat(12)8
Avg EPS beat(12)7.54%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-36.8%
PT rev (3m)-36.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.99
EYN/A
EPS(NY)-6.35
Fwd EYN/A
FCF(TTM)-6.65
FCFYN/A
OCF(TTM)-6.65
OCFYN/A
SpS0
BVpS-0.75
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -214.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.59%
ROA(5y)-101.87%
ROE(3y)-126.09%
ROE(5y)-751.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 1.04
Altman-Z -21.03
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.76%
EPS Next Y69.73%
EPS Next 2Y40.53%
EPS Next 3Y51.95%
EPS Next 5Y43.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-51.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.18%
OCF growth 3YN/A
OCF growth 5YN/A

QUOIN PHARMACEUTICALS LT-ADR / QNRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to QNRX.


Can you provide the valuation status for QUOIN PHARMACEUTICALS LT-ADR?

ChartMill assigns a valuation rating of 1 / 10 to QUOIN PHARMACEUTICALS LT-ADR (QNRX). This can be considered as Overvalued.


What is the profitability of QNRX stock?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for QUOIN PHARMACEUTICALS LT-ADR?

The Earnings per Share (EPS) of QUOIN PHARMACEUTICALS LT-ADR (QNRX) is expected to grow by 69.73% in the next year.